DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Brivanib

First Posted Date: 2006-10-23

Last Posted Date: 2011-01-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 13

Registration Number: NCT00390936

Locations: 🇯🇵
Local Institution, Sunto-Gun, Shizuoka, Japan

First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy

Phase 2

Completed

Conditions: Metastasis
Bladder Cancer
Transitional Cell Carcinoma

Interventions: Drug: Vinflunine
Other: Placebo
Drug: Gemcitabine

First Posted Date: 2006-10-18

Last Posted Date: 2015-12-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 34

Registration Number: NCT00389155

Locations: 🇺🇸
Medical College Of Georgia, Augusta, Georgia, United States
🇺🇸
Nevada Cancer Centers, Las Vegas, Nevada, United States
🇺🇸
Acrc/Arizona Clinical Research Center, Inc., Tucson, Arizona, United States

and more 55 locations

Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: Other anti-HBV medication
Drug: entecavir

First Posted Date: 2006-10-17

Last Posted Date: 2018-07-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 12522

Registration Number: NCT00388674

Locations: 🇺🇸
Office Of Sing Chan Md, Flushing, New York, United States
🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇺🇸
Scti Research Foundation, Coronado, California, United States

and more 18 locations

Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects

Phase 2

Terminated

Conditions: Obesity

Interventions: Drug: BMS-646256
Drug: Placebo

First Posted Date: 2006-10-17

Last Posted Date: 2010-09-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 705

Registration Number: NCT00388609

Locations: 🇺🇸
Domenica M. Rubino, Md, Washington, District of Columbia, United States
🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
🇺🇸
Springfield Diabetes And Endocrine Center, Springfield, Illinois, United States

and more 7 locations

Effect of Ketoconazole on the Pharmacokinetics of Vinflunine

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: vinflunine + ketaconazole

First Posted Date: 2006-10-17

Last Posted Date: 2016-09-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 35

Registration Number: NCT00388557

Locations: 🇺🇸
Tennessee Oncology, Pllc, Nashville, Tennessee, United States

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: dasatinib

First Posted Date: 2006-10-09

Last Posted Date: 2013-04-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 94

Registration Number: NCT00385580

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
The Bunting Blaustein Cancer Research Building, Baltimore, Maryland, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 5 locations

Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine
Drug: Atazanavir/Ritonavir
Drug: Atazanavir/Ritonavir + Famotidine

First Posted Date: 2006-10-06

Last Posted Date: 2010-02-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 40

Registration Number: NCT00384904

Locations: 🇬🇧
Local Institution, London, Greater London, United Kingdom
🇺🇸
Garden State Infectious Disease Associates, Pa, Voorhees, New Jersey, United States
🇺🇸
Unc Center For Aids Research, Chapel-Hill, North Carolina, United States

Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22)

Phase 4

Completed

Conditions: Actue Coronary Syndromes

First Posted Date: 2006-09-29

Last Posted Date: 2011-04-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 4000

Registration Number: NCT00382460

A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug

Completed

Conditions: Liver Diseases

Interventions: Drug: Dasatinib

First Posted Date: 2006-09-29

Last Posted Date: 2011-04-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 40

Registration Number: NCT00382668

Locations: 🇺🇸
University Of Miami, Miami, Florida, United States
🇺🇸
New Orleans Center For Clinical Research, Knoxville, Tennessee, United States
🇺🇸
Comprehensive Phase One, Miramar, Florida, United States

and more 1 locations

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Metastasis

Interventions: Drug: Dasatinib
Drug: Dasatinib 100 mg

First Posted Date: 2006-09-04

Last Posted Date: 2011-04-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 92

Registration Number: NCT00371345

Locations: 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸
Ucsf-Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy